Data analytics firm Diaceutics will consider a future Dublin listing.

Shares in the pharmaceutical industry-focused firm closed up more than 25pc on their first day of trading on London’s AIM market yesterday.

Chief executive Peter Keeling told the Irish Independent yesterday that a dual Dublin-London listing was “one of the options” ahead of the decision to list on AIM only.

“We would rule nothing out at this stage. I recognise, because it has already been mentioned to us several times, that we actually do have a lot of support across the island of Ireland,” Mr Keeling said.

“Obviously, the AIM market feels as though we’ve taken a side step from that, and that’s not the intention. So I think somehow we’ll always make sure that we’re encompassing that Irish dimension of our business, because it’s really important to us.”

He said, however, that listing here was “not on the cards in the immediate future”.

The company raised £17m (€19.5m) in listing yesterday, which will be used to boost its analytics offering.

Mr Keeling said he had chosen to go public because he “wanted to make sure that every time we came back to look for additional funds that it wasn’t going to take months and months and months”.

He said the transparency that goes with being a public entity would boost client confidence.

Source: Read Full Article